Wegovy (semaglutide) is the higher-dose version of Ozempic approved for chronic weight management. Because the maintenance dose (2.4 mg) is higher than Ozempic (typically 1.0 to 2.0 mg), Wegovy produces faster and larger weight loss in most users. The STEP clinical trial program is the gold standard data set for Wegovy timelines.
This guide walks through what to expect at each phase, factors that change your individual timeline, and how meal delivery supports Wegovy users during the slow appetite phases.
Appetite suppression begins within the first week at 0.25 mg. By week 2 most users describe smaller portion sizes, earlier fullness, and reduced cravings. The 0.25 mg starting dose is a tolerance ramp. Weight loss in this phase is small (1 to 3 pounds) and primarily water weight as the body adjusts.
Significant weight loss begins after dose escalation to 0.5, 1.0, 1.7 mg over the first 16 weeks. By week 16 average loss in STEP trials was 7 to 10 percent of starting body weight. Loss continues at 0.5 to 1 percent per week during the climb. Side effects often peak during these escalation phases.
Full effect is reached at 2.4 mg maintenance dose around week 17. By month 6 most patients have lost 12 to 15 percent of body weight. STEP 1 trial showed 14.9 percent average loss at 68 weeks. Plateaus are common after month 9 and often resolve with continued behavior reinforcement.
| Week | Dose | Typical effect |
|---|---|---|
| Weeks 1 to 4 | 0.25 mg weekly | Tolerance ramp. Appetite drops, mild nausea common, weight loss 1 to 3 pounds. |
| Weeks 5 to 8 | 0.5 mg weekly | Therapeutic dose begins. Weight loss 1 to 2 pounds per week for many users. |
| Weeks 9 to 12 | 1.0 mg weekly | Steady loss continues. Side effects often peak this window. |
| Weeks 13 to 16 | 1.7 mg weekly | Climbing to full dose. Average loss reaches 7 to 10 percent. |
| Weeks 17+ | 2.4 mg weekly (maintenance) | Full Wegovy effect. Average 14.9 percent loss at 68 weeks. |
Wegovy users often need help maintaining adequate nutrition during low appetite phases. Meal delivery provides consistent protein and removes the planning load. The services below are all built for portioned eating with explicit per meal protein numbers.
Full ranking at our GLP 1 meal delivery hub.
Appetite suppression starts within the first week. Measurable weight loss begins at weeks 4 to 8. Full therapeutic effect at the 2.4 mg maintenance dose is reached at week 17. Average loss at 68 weeks is 14.9 percent.
Same molecule (semaglutide) but Wegovy reaches a higher maintenance dose (2.4 mg vs 1.0 to 2.0 mg for Ozempic). Wegovy typically produces larger and faster weight loss because of the higher dose. Side effects are also more pronounced.
Most users plateau at month 9 to 14 on the 2.4 mg maintenance dose. Plateaus do not mean the medication has stopped working. They usually resolve with continued behavior reinforcement or further dietary refinement.
Appetite suppression starts in the first week but the early weeks at 0.25 mg are a tolerance ramp, not a therapeutic dose. Most users do not see dramatic weight loss until weeks 5 to 8 when the dose escalates to 0.5 and 1.0 mg.
STEP 1 clinical trial showed average 14.9 percent body weight loss at 68 weeks. Some patients lose more, some less. Higher starting BMI usually means more pounds lost.
Common reasons: still in the early escalation phase (give it 16 weeks to reach full dose), not enough protein, sleep deprivation, plateau at month 9+ (often resolved by behavior reinforcement). Discuss with your prescriber if no change by week 16.
Answer 5 quick questions. We'll match you to the top 3 from 24 services we track.